





INDIAN CLINICAL TRIAL AND EDUCATION NETWORK



Clinical Validation of In-Vitro Diagnostics



Date 28 February 2025

Time 04:00 PM IST



https://echo.zoom.us/j/86030306283



File No. VIR/COVIT 19/28 2020/ECD-1/PL2 ELC. (C) mputer No. 121915) Generated from eOffice by GUNJAN KUMAR, SC-D(GK), SCIENTIST D, ICMR on 20/02/2025 01:41 pm



INDIAN CI ICAL TRIAL AND EDI

icma

WEBINAR

(((•)))

998316/2025/Development Research

Clinical Validation of In-Vitro Diagnostics

28 February 2025

AGENDA

Time	Session	Speaker/Panelists
4:00-4:05 PM	Welcome Address	Dr Aparna Mukherjee Scientist F & Head Clinical Studies & Trials Unit, ICMR HQ, New Delhi
4:05-4:50 PM	Clinical Validation of In-Vitro Diagnostics	Dr Rucha Patil Scientist D, Department of Haemostasis and Thrombosis, ICMR- National Institute of Immunohaematology, Mumbai
4:50-5:00 PM	Question & Answers	All participants



https://echo.zoom.us/j/86030306283

ORGANIZED BY

Indian Clinical Trial and Education Network Clinical Studies & Trials Unit, Division of Development Research, Indian Council of Medical Research, Department of Health Research, New Delhi²- 110029

INDIAN CLINICAL TRIAL AND EDUCATION NETWORK

icma

(•••) WEBINAR

• I IVF

VEBINA

998316/2025/Development Research

Clinical Validation of In-Vitro Diagnostics 28 February 2025

https://echo.zoom.us/j/86030306283



SPEAKER

Dr Rucha Patil, Scientist D, Department of Haemostasis and Thrombosis, ICMR – National Institute of Immunohaematology, Mumbai

RCT

Area of Interest: Haemostasis and Thrombosis, cell derived Microparticles, Development of point of care and simple tests, Academic clinical trials for haemophilia, etc

Career Highlights:

- **Technology development**: Qualitative G6PD POC, COVID antibody POC, Validation of FVIII and VWD POC
- **Randomized clinical trial**: Lower dose of emicizumab prophylaxis, after publication has resulted in >100 patients all over India on the low dose.
- Member of Internationally recognized Haemophilia comprehensive care center: KEM, ICMR-NIIH
- Member, Indian Society of Hematology and Transfusion Medicine- L-1682
- Appointed as Secretary of Mumbai Haematology Group in February 2019

ORGANIZED BY

Indian Clinical Trial and Education Network

Clinical Studies & Trials Unit, Division of Development Research, Indian Council of Medical Research, Department of Health Research, New Delhi³– 110029